Immunology Today, voL 5, No. 11, 1984
309
The Immunodeficiency-Cancer Registry is renewed People with naturally occurring (primary or genetically determined) immunodeficiency have an abnormally high incidence oftumours. This association has been reported worldwide and in 1973 an attempt was begun in Minneapolis to collect systematically all the data relevant to its incidence and origins. The Immunodeficiency-C ancer Registry (ICR) has had recent funding difficulties but has now been re-established with full time management. The I C R collects reports of tumours (including non-melanoma skin cancer) associated with the 14 categories of naturally occurring immunodeficiency
disorders defined by the W H O Scientific Group on Immunodeficiency. These are provided by physicians either directly to the I C R or via publications. In future, data will be collected on other disorders of immunity and pre-malignant lesions. The distribution of malignancies currently known to the I C R is shown in Table I. Because the nature and extent of the immune deficits and associated abnormalities differ among the naturally occurring immunodeficiency syndromes, the systematic collection of these rate cases may provide a means of identifying links between certain types of immune dysfunction and susceptibility to cancer.
I t may also give insights into cancer risk factors in patients with acquired immunodeficiencies or immunologicaUy normal people. The I C R database is available for consultation by all interested clinicians and scientists and financial reimbursement is available for registration of new cases. Contact should be made through: A. H. Filopovich M. D., Principal Investigator; or Valerie Stoker, M.P.H., Immunodeficiency-Cancer Registry, Box 610 Mayo, University of Minnesota Minneapolis, M N 55455, USA. []
TABLE I. Histologic type of first malignancy registered with Immunodeficiency-Cancer Registry, April 1973-June 1984 Immunodeficiency Ataxia-telangiectasia Common variable irnmunodeficiency Wiskott-Aldrich syndrome Severe combined immunodeficiency Immunoglobulin defects" Others b Total
Non-Hodgkin's lymphoma 61 43 47 26 22 1 200 (43%)
Hodgkin's disease 12 5 3 1 10 0 31 (7%)
Leukemia
Carcinoma
Others
Total
29 7
25 39
18 20
145 (31% ) 114 (24 %)
5 4
2 1
17 5
74 (16%) 37 (8%)
11 2 58 (12%)
9 0 76 (16%)
31 12 103 (22%)
83 (18%) 15 (3%) 468 (100%)
~Hypogammaglobulinemia, including Bmton's agammaglobulinemia, selective IgA deficiency, hyper-IgE syndrome, and immunodeficiency with hyper-IgM. bImmunodeficiency with thymoma, immunodeficiency with generalized hematopoeitic hypoplasia, DiGeorge syndrome, and transient hypogammaglobulinemia of infancy.
309
The Immunodeficiency-Cancer Registry is renewed People with naturally occurring (primary or genetically determined) immunodeficiency have an abnormally high incidence oftumours. This association has been reported worldwide and in 1973 an attempt was begun in Minneapolis to collect systematically all the data relevant to its incidence and origins. The Immunodeficiency-C ancer Registry (ICR) has had recent funding difficulties but has now been re-established with full time management. The I C R collects reports of tumours (including non-melanoma skin cancer) associated with the 14 categories of naturally occurring immunodeficiency
disorders defined by the W H O Scientific Group on Immunodeficiency. These are provided by physicians either directly to the I C R or via publications. In future, data will be collected on other disorders of immunity and pre-malignant lesions. The distribution of malignancies currently known to the I C R is shown in Table I. Because the nature and extent of the immune deficits and associated abnormalities differ among the naturally occurring immunodeficiency syndromes, the systematic collection of these rate cases may provide a means of identifying links between certain types of immune dysfunction and susceptibility to cancer.
I t may also give insights into cancer risk factors in patients with acquired immunodeficiencies or immunologicaUy normal people. The I C R database is available for consultation by all interested clinicians and scientists and financial reimbursement is available for registration of new cases. Contact should be made through: A. H. Filopovich M. D., Principal Investigator; or Valerie Stoker, M.P.H., Immunodeficiency-Cancer Registry, Box 610 Mayo, University of Minnesota Minneapolis, M N 55455, USA. []
TABLE I. Histologic type of first malignancy registered with Immunodeficiency-Cancer Registry, April 1973-June 1984 Immunodeficiency Ataxia-telangiectasia Common variable irnmunodeficiency Wiskott-Aldrich syndrome Severe combined immunodeficiency Immunoglobulin defects" Others b Total
Non-Hodgkin's lymphoma 61 43 47 26 22 1 200 (43%)
Hodgkin's disease 12 5 3 1 10 0 31 (7%)
Leukemia
Carcinoma
Others
Total
29 7
25 39
18 20
145 (31% ) 114 (24 %)
5 4
2 1
17 5
74 (16%) 37 (8%)
11 2 58 (12%)
9 0 76 (16%)
31 12 103 (22%)
83 (18%) 15 (3%) 468 (100%)
~Hypogammaglobulinemia, including Bmton's agammaglobulinemia, selective IgA deficiency, hyper-IgE syndrome, and immunodeficiency with hyper-IgM. bImmunodeficiency with thymoma, immunodeficiency with generalized hematopoeitic hypoplasia, DiGeorge syndrome, and transient hypogammaglobulinemia of infancy.
